Ftse Mib
37.790,53
0,55%
DAX
22.073,96
0,18%
S&P 500
6.068,50
0,03%
NASDAQ
19.643,86
-0,36%
Bitcoin
96.215,81
0,49%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Eagle Capital Growth Fund Inc (GRF) Eagle Capital Growth Fund Inc (GRF) Notizie

Eagle Capital Growth Fund Inc

GRF
9,95
0,00 (0,00%)
12 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/1/202512:00GLOBEGrifols Pioneers High-Tech Analysis of Plasma Bank to Detect..
26/12/202419:40EDGAR2Form 40-17G - Fidelity Bond [Rule 17G-1(g)]
05/12/202421:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/11/202414:00GLOBEGigaGen Doses First Patient in Phase 1 Trial of Recombinant..
18/11/202422:00BWEagle Capital Growth Fund Declares Year-End Distribution of..
29/10/202413:00GLOBEGrifols Receives FDA Approval to Treat Surgical Bleeding in..
22/10/202414:00GLOBEGrifols Partners with BARDA for Proof-of-Concept Testing of..
03/10/202416:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202414:00GLOBEGigaGen Awarded U.S. BARDA Contract to Develop Recombinant..
10/9/202419:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202419:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202414:00GLOBEGigaGen Receives FDA Clearance of IND Application for Phase..
29/7/202414:00GLOBEGrifols receives expanded XEMBIFY® (immune globulin..
01/7/202412:00GLOBEGrifols’ Biotest to achieve USD 1 billion in US sales of..
18/6/202413:30GLOBEGrifols completes sale of a 20% equity stake in SRAAS and..
17/6/202410:20GLOBEGrifols’ Biotest receives FDA approval for innovative..
24/5/202421:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/4/202415:30GLOBEGrifols Celebrates 50 Years of Manufacturing Life-Changing..
04/4/202410:00GLOBEGrifols Procleix ArboPlex Assay® Receives CE Mark, the First..
07/3/202417:11EDGAR2Form DEF 14A - Other definitive proxy statements
06/3/202418:56EDGAR2Form N-CSR - Certified Shareholder Report
23/2/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202409:16GLOBEGrifols announces positive topline phase 3 fibrinogen..
13/2/202421:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202421:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 9,95

La tua Cronologia

AMEX
GRF
Eagle Capital Growth
NYSE
PCN
PIMCO Corporate and Inco...
BIT
1CVAC
CureVac BV
AQSE
FUSI.GB
FIL Fund Management Irel...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci